Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Aug 4;10:13108. doi: 10.1038/s41598-020-69809-y

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

COX-2 and L-PGDS inhibitors suppressed the proliferation of prostate cells induced by BPA and promoted apoptosis. Effect of the COX-2 and L-PGDS inhibitors on the viability of HPEpiC (a) and HPrF (b); Effect of the COX-2 and L-PGDS inhibitors on HPEpiC (c) and HPrF (d). (HPEpiC: human prostate epithelial cells; HPrF: human prostate fibroblasts. FL1: FITC channel, FL3: PI channel; B2: FITC+/PI+, late stage apoptotic cells; B3: FITC-/PI−, normal cells; B4: FITC+/PI−, viable apoptotic cells; NS398: COX-2 inhibitor, AT56: L-PGD inhibitor).